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Purpose
Children with systemic sclerosis (SSc) may develop severe
alveolitis with progressive, potentially fatal interstitial
fibrosis. There have been no controlled trials for treatment
of juvenile SSc. Adult trials suggest benefit from cyclopho-
sphamide (CY) therapy, though with significant risk for
adverse events. As part of a larger study to develop objec-
tive clinical and radiological measures for outcomes in
juvenile SSc, we reviewed the courses of seven patients
with SSc lung disease who were treated with extensive
courses of CY or methotrexate.
Methods
Medical records were reviewed for all patients diagnosed
with scleroderma at Seattle Children’s Hospital during the
years 1994 to 2010 to identify children who fulfilled ACR
criteria for systemic sclerosis. Nineteen patients were iden-
tified: 15 girls and four boys. Eleven patients developed
pulmonary fibrosis and/or alveolitis detected by high reso-
lution CT scan. Further review was conducted of records
for seven patients with pulmonary SSc followed for a
mean of 6.4 years (range 4.1-9.6). The mean age at diagno-
sis was 10.8 years (range 6-14.7).
Results
The DLCO adjusted for alveolar volume (DLCO) prior to
therapy averaged 81.9%, ranging from 68-99% of normal.
Five patients (mean DLCO 79.6%, range 68-99%) were trea-
ted with CY at the first sign of alveolitis. The CY treatment
regimen included oral CY (1-3 mg/kg/day) and/or IV CY
(750 mg/m2/month) for an average of 1.6 years (range 0.5
to 3). The cumulative CY doses averaged 19 grams (range 7
to 28.1 grams). Two patients (DLCO 81% and 94%) were
treated with methotrexate 1 mg/kg, with a maxiumum
40 mg, subcutaneously once a week. Corticosteroids were
administered to all patients. We found that three of the five
CY patients had improved pulmonary function at the last
test, with a mean decrease in DLCO of 2.2% (range -14 to
+5%, mean -0.43%/year). Patients on methotrexate were
stable with DLCO improving in one (81 to 102%) and
decreasing in one (94% to 81%). Serial CT scans showed
stable or improved disease (by estimated area of alveolitis
and/or fibrosis) in all seven patients. During or after CY
therapy there was one hospitalization for possible serious
infection, eventually attributed to antibiotic-induced pneu-
monitis, and one case of otitis media. One patient had mild
gastritis that resolved with a reduction in oral CY dose.
Pulmonary hypertension was detected and resolved in three
patients. No malignancies developed.
Conclusion
Juvenile SSc patients with severe SSc lung disease can
stabilize and even improve with cyclophosphamide or
methotrexate and corticosteroid therapy. The low short-
term rate of adverse events reported here and high rate
of morbidity and mortality of SSc without treatment
argues for the benefit of cyclophosphamide or metho-
trexate in children with SSc lung disease.
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